diffuse large B-cell lymphoma

Role of c-MYC, BCL2, and BCL6 Expression in Pathogenesis of Diffuse Large B-Cell Lymphoma

REVIEWS , , , , ,

A.E. Misyurina1, V.A. Misyurin2, E.A. Baryakh1, A.M. Kovrigina1, S.K. Kravchenko1

1 Hematology Research Center under the Ministry of Health of the Russian Federation, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

2 N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: A.E. Misyurina, Graduate student 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel: +7(909)637-32-49; e-mail: anna.lukina1@gmail.com

For citation: Misyurina A.E., Misyurin V.A., Baryakh E.A., Kovrigina A.M., Kravchenko S.K. Role of c-MYC, BCL2, and BCL6 Expression in Pathogenesis of Diffuse Large B-Cell Lymphoma. Klin. Onkogematol. 2014; 7(4): 512–521 (In Russ.).

ABSTRACT

According to modern concepts based on results of examination of the gene expression profile, there are several subtypes of diffuse large B cell lymphoma (DLBCL): germinal center B cell-like (GCB) and activated B cell-like (ABC) lymphomas. Genes c-MYC, BCL6, and BCL2 are key regulators of B-cell germinal (follicular) differentiation. Genetic abnormalities with their participation are most common in molecular pathogenesis of DLBCL. A total level of activity as well as mechanisms that lead to overexpression each of these genes and production of corresponding proteins have an impact on a disease prognosis. We assume that quantitative assay of c-MYC, BCL6, and BCL2 gene expression, as well as proteins encoded by these genes, can allow to determine high risk DLBCL patients with great accuracy.

Keywords: diffuse large B cell lymphoma, molecular subtypes, risk groups, c-MYC, BCL6, BCL2.

Accepted: September 8, 2014

Read in PDF (RUS)pdficon

REFERENCES

  1. Swerdlow S.H., Campo E., Harris N.L. et al (eds.). WHO Classification of Tumors of Haematopoetic and Lymphoid Tissues. Lyon: IARC, 2008: 233–4.
  2. Frick M., Dorken B., Lenz G. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. Best Pract. Res. Clin. Haematol. 2012; 25(1): 3–12.
  3. Alizadeh A.A., Eisen M.B., Davis R.E. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503–11.
  4. Rosenwald A., Wright G., Chan W.C. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346(25): 1937–47.
  5. Alizadeh A.A., Eisen M.B., Davis R.E. et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor Symp. Quant. Biol. 1999; 62: 71–8.
  6. Lenz G., Wright G., Dave S.S. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008; 359(22): 2313–23.
  7. Rosenwald A., Wright G., Leroy K. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 2003; 198(6): 851–62.
  8. Savage K.J., Monti S., Kutok J.L. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003; 102(12): 3871–9.
  9. Wright G., Tan B., Rosenwald A. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA. 2003; 100: 9991–6.
  10. Muller A.M., Medvinsky A., Strouboulis J., Grosveld F., Dzierzak E. Development of hematopoietic stem cell activity in the mouse embryo. Immunity. 1994; 1: 291–301.
  11. Melchers F. The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat. Rev. Immunol. 2005; 5: 578–84.
  12. van Zelm M.C., Szczepanski T., van der Burg M., van Dongen J.J. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J. Exp. Med. 2007; 204: 645–55.
  13. Martin F., Oliver A.M., Kearney J.F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity. 2001; 14: 617–29.
  14. Chen J., Trounstine M., Alt F.W. et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 1993; 5: 647–56.
  15. Teng G., Papavasiliou F.N. Immunoglobulin somatic hypermutation. Annu. Rev. Genet. 2007; 41: 107–20.
  16. Liu Y.J., Arpin C. Germinal center development. Immunol. Rev. 1997; 156: 111–26.
  17. Yuan D. Regulation of IgM and IgD synthesis in B lymphocytes. II. Translational and post-translational events. J. Immunol. 1984; 132: 1566–70.
  18. Yasodha N. The Biology of the Germinal Center. ASH Education Book. 2007; 1: 210–5.
  19. Komori T., Okada A., Stewart V., Alt F.W. Lack of N regions in antigen receptor variable region genes of TdT-deficient lymphocytes. Science. 1993; 261: 1171–5.
  20. Willenbrock K., Jungnickel B., Hansmann M.L., Kuppers R. Human splenic marginal zone B cells lack expression of activation-induced cytidine deaminase. Eur. J. Immunol. 2005; 35: 3002–7.
  21. Raghavan S.C., Hsieh C.L., Lieber M.R. Both V(D)J coding ends but neither signal end can recombine at the bcl-2 major breakpoint region, and the rejoining is ligase IV dependent. Mol. Cell. Biol. 2005; 15: 6475–84.
  22. Luscher B. MAD1 and its life as a MYC antagonist: an update. Eur. J. Cell. Biol. 2012; 91(6–7): 506–14.
  23. McDuff F.O., Naud J.F., Montagne M., Sauve S., Lavigne P. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis. J. Mol. Recognit. 2009; 22(4): 261–9.
  24. Dang C.V. MYC on the path to cancer. Cell. 2012; 149(1): 22–35.
  25. Luscher B., Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene. 2012; 494(2): 145–60.
  26. Meyer N., Penn L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer. 2008; 8(12): 976–90.
  27. Keller U.B., Old J.B., Dorsey F.C. et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphoma agenesis. EMBO. J. 2007; 26(10): 2562–74.
  28. Bueno M.J., Malumbres M. MicroRNAs and the cell cycle. Biochim. Biophys. Acta. 2011; 1812(5): 592–601.
  29. Nie Z., Hu G., Wei G. et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1): 68–79.
  30. Lin C.Y., Loven J., Rahl P.B. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151(1): 56–67.
  31. Lin Y., Wong K., Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997; 276(5312): 596–9.
  32. Basso K., Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv. Immunol. 2010; 105: 193–210.
  33. Phan R.T., Saito M., Basso K., Niu H., Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat. Immunol. 2005; 6(10): 1054–60.
  34. Niu H., Ye B.H., Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 1998; 12(13): 1953–61.
  35. Phan R.T., Saito M., Kitagawa Y., Means A.R., Dalla-Favera R. Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. Nat. Immunol. 2007; 8(10): 1132–9.
  36. Phan R.T., Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004; 432(7017): 635–9.
  37. Basso K., Saito M., Sumazin P. et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010; 115(5): 975–84.
  38. Wagner S.D., Ahearne M., Ko Ferrigno P. The role of BCL6 in lymphomas and routes to therapy. Br. J. Haematol. 2011; 152(1): 3–12.
  39. Basso K., Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol. Rev. 2012; 247(1): 172–83.
  40. Merino R., Ding L., Veis D.J. et al. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO. J. 1994; 13: 683–91.
  41. McDonnell T.J., Nunez G., Platt F.M. et al. Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol. Cell. Biol. 1990; 10: 1901–7.
  42. McDonnell T.J., Deane N., Platt F.M. et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989; 57: 79–88.
  43. Veis D.J., Sorenson C.M., Shutter J.R. et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 1993; 75: 229–40.
  44. Wilson W.H., Teruya-Feldstein J., Fest T. et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood. 1997; 89: 601–9.
  45. Monti S., Savage K.J., Kutok J.L. et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005; 105(5): 1851–61.
  46. Dent A.L., Shaffer A.L., Yu X. et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997; 276(5312): 589–92.
  47. Никитин Е.А. Патогенез зрелоклеточных лимфатических опухолей. Материалы конгрессов и конференций. VIII Российский онкологический конгресс [Электронный документ] (http://www.rosoncoweb.ru/library/ congress/ru/08/19.php). [Nikitin E.A. Pathogenesis of mature cell lymphomas. Materialy kongressov i konferentsii. VIII Rossiiskii onkologicheskii kongress (Materials of congresses and conferences. VIII Russian oncological congress). Available at: http://www. rosoncoweb.ru/library/congress/ru/08/19.php (In Russ.)]
  48. Davis R.E., Brown K.D., Siebenlist U. et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001; 194(12): 1861–74.
  49. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007; 109(7): 2700–7.
  50. Ngo V.N., Davis R.E., Lamy L. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006; 441(7089): 106–10.
  51. Rawlings D.J., Sommer K., Moreno-Garcia M.E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat. Rev. Immunol. 2006; 6(11): 799–812.
  52. Lenz G., Davis R.E., Ngo V.N. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008; 319(5870): 1676–9.
  53. Davis R.E., Ngo V.N., Lenz G. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463(7277): 88–92.
  54. Compagno M., Lim W.K., Grunn A. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247): 717–21.
  55. Kato M., Sanada M., Kato I. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009; 459(7247): 712–6.
  56. Ding B.B., Yu J.J., Yu R.Y. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large Bcell lymphomas. Blood. 2008; 111(3): 1515–23.
  57. Lam L.T., Wright G., Davis R.E. et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008; 111(7): 3701–13.
  58. Ngo V.N., Young R.M., Schmitz R. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011; 470(7332): 115–9.
  59. Bea S., Zettl A., Wright G. et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve geneexpression-based survival prediction. Blood. 2005; 106(9): 3183–90.
  60. Boerma E.G., Siebert R., Kluin P.M., Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today’s knowledge. Leukemia. 2009; 23(2): 225–34.
  61. Salaverria I., Zettl A., Bea S. et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt’s lymphoma. Haematologica. 2008; 93(9): 1327–34.
  62. Scholtysik R., Kreuz M., Klapper W. et al. Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010; 95(12): 2047–55.
  63. Pasqualucci L., Neumeister P., Goossens T. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001; 412(6844): 341–6.
  64. Hemann M.T., Bric A., Teruya-Feldstein J. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005; 436(7052): 807–11.
  65. Giulino-Roth L., Wang K., MacDonald T.Y. et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood. 2012; 120(26): 5181–4.
  66. Bhatia K., Huppi K., Spangler G. et al. Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas. Nat. Genet. 1993; 5(1): 56–61.
  67. Snuderl M., Kolman O.K., Chen Y.B. et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2010; 34(3): 327–40.
  68. Le Gouill S., Talmant P., Touzeau C. et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007; 92(10): 1335–42.
  69. Li S., Lin P., Fayad L.E. et al. B-cell lymphomas with B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod. Pathol. 2012; 25(1): 145–56.
  70. Klapper W., Stoecklein H., Zeynalova S. et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leukemia. 2008; 22(12): 2226–9.
  71. Savage K.J., Johnson N.A., Ben-Neriah S. et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114(17): 3533–7.
  72. Horn H., Ziepert M., Becher C. et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12): 2253–63.
  73. Barrans S., Crouch S., Smith A. et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J. Clin. Oncol. 2010; 28(20): 3360–5.
  74. Valera A., Lopez-Guillermo A., Cardesa-Salzman T. et al. MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98(10): 1554–62.
  75. Hummel M., Bentink S., Berger H. et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006; 354(23): 2419–30.
  76. Salaverria I., Siebert R. The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J. Clin. Oncol. 2011; 29(14): 1835–43.
  77. Bertrand P., Bastard C., Maingonnat C. et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007; 21(3): 515–23.
  78. Tomita N. BCL2 and MYC Dual-Hit Lymphoma/Leukemia. J. Clin. Exp. Hematopathol. 2011; 51(1): 7–12.
  79. Johnson N.A., Savage K.J., Ludkovski O. et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009; 114(11): 2273–9.
  80. Snuderl M., Kolman O.K., Chen Y.B. et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2010; 34(3): 327–40.
  81. Hoeller S., Copie-Bergman C. Grey Zone Lymphomas: Lymphomas with Intermediate Features. Advances in Hematology 2012. http://dx.doi. org/10.1155/2012/460801.
  82. Tauro S., Cochrane L., Lauritzsen G.F. et al. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (< 50 years): A comparison of two adapted BFM protocols. Am. J. Hematol. 2010; 85(4): 261–3.
  83. Kobayashi T., Tsutsumi Y., Sakamoto N. et al. Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab. Jpn. J. Clin. Oncol. 2012; 42(11): 1035–42.
  84. Fanidi A., Harrington E.A., Evan G.I. Cooperative in reactions between c-myc and bcl-2 protooncogenes. Nature. 1992; 359: 554–6.
  85. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335(6189): 440–2.
  86. Zhaohui J., Stratford M.W., Fengqin G., Tammy F., Xingming D. Bcl2 suppresses DNA repair by enhancing c-myc transcriptional activity. J. Biol. Chem. 2005; 281: 14446–56.
  87. Masao N., Shinobu T., Keiichiro H., Osamu T., Masao S. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells. Haematologica. 2011; 96(9): 1318–26.
  88. DeoCampo N.D., Wilson M.R., Trosko J.E. Cooperation of bcl-2 and myc in the neoplastic transformation of normal rat liver epithelial cells is related to the down-regulation of gap junction-mediated intercellular communication. Carcinogenesis. 2000; 21(8): 1501–6.
  89. Leucci E., Cocco M., Onnis A. et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J. Pathol. 2008; 216(4): 440–50.
  90. Onnis A., De Falco G., Antonicelli G. et al. Аlteration of microRNAs regulated by c-MYC in Burkitt lymphoma. PLoS One. 2010; 5(9); e12960.
  91. Stasik C.J., Nitta H., Zhang W. et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica. 2010; 95(4): 597–603.
  92. Schrader A., Bentink S., Spang R. et al. High MYC activity is an independent negative prognostic factor for DLBCL. Cancer. 2012; 131(4): 348–61.
  93. Yoon S.O., Jeon Y.K., Paik J.H. et al. MYC translocation and an increased copy number predict poor prognosis in adult DLBCL, especially in GCB-type. Histopathology. 2008; 53(2): 205–17.
  94. Mossafa H., Damotte D., Jenabian A. et al. Non-Hodgkin lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk. Lymphoma. 2006; 47(9): 1885–93.
  95. Martin-Subero J.I., Odero M.D., Hernandez R. et al. Amplification of IGH/ MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes Cancer. 2005; 43(4): 414–23.
  96. Tapia G., Lopez R., Munoz-Marmol A.M. et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B-cell lymphoma. Histopathology. 2011; 59(4): 672–8.
  97. Green T.M., Nielsen O., de SK. et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2012; 36(4): 612–9.
  98. Johnson N.A., Slack G.W., Savage K.J. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30(28): 3452–9.
  99. Kluk M.J., Chapuy B., Sinha P. et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012; 7(4): e33813.
  100. Testoni M., Kwee I., Greiner T.C. et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br. J. Haematol. 2011; 155(2): 274–7.
  101. Hu S., Xu-Monette Z.Y., Tzankov A. et al. MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013; 121(20): 4021–31.
  102. Piris M.A., Pezzella F., Martinez-Montero J.C. et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br. J. Cancer. 1994; 69: 337–41.
  103. Tang S.C., Visser L., Hepperle B. et al. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin’s lymphoma: An analysis of 83 cases. J. Clin. Oncol. 1994; 12: 149–54.
  104. Barrans S.L., Carter I., Owen R.G. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002; 99: 1136–43.
  105. Colomo L., Lopez-Guillermo A., Perales M. et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003; 101: 78–84.
  106. Gascoyne R.D., Adomat S.A., Krajewski S. et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997; 90: 244–51.
  107. Martinka M., Comeau T., Foyle A. et al. Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma. Clin. Invest. Med. 1997; 20: 364–70.
  108. Hill M.E., MacLennan K.A., Cunningham D.C. et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in dif- fuse large cell non-Hodgkin’s lymphoma: A British National Lymphoma Investigation Study. Blood. 1996; 88: 1046–51.
  109. Kramer M.H., Hermans J., Wijburg E. et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998; 92: 3152–62.
  110. Hermine O., Haioun C., Lepage E. et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma: Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996; 87: 265–72.
  111. Iqbal J., Neppalli V.T., Wright G., Dave B.J. BCL2 Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2006; 24(6): 961–8.
  112. Green T.M., Young K.H., Visco C. et al. Immunohistochemical DoubleHit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J. Clin. Oncol. 2012; 30(28): 3460–7.
  113. Johnson N.A., Slack G.W., Savage K.J. et al. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J. Clin. Oncol. 2012; 30(28): 3452–9.
  114. Valera A., Lopez-Guillermo A., Cardesa-Salzmann T. et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98(10): 1554–62.

Importance of biochemical studies of brain natriuretic peptide in patients with diffuse large B-cell lymphoma

LABORATORY DIAGNOSIS , , ,

M.O. Yegorova, Ye.N. Komolova, and S.Ye. Samsonova

Hematology Research Center, RF Ministry of Health, Moscow, Russian Federation

ABSTRACT

In this study, we measured the levels of the brain natriuretic peptide (BNP) in the blood of patients with diffuse large B-cell lymphoma (DBCL) before and after polychemotherapy. The study included 10 patients: 6 males and 4 females at the age of 39 to 63 (mean age = 51 ± 12). The control group consisted of 20 virtually healthy donors. It was shown that measurements of BNP plasma levels in DBCL could identify the patients with the high risk of heart failure. Screening tests with determination of BNP levels can influence the choice of chemotherapy for DBCL.

Keywords: diffuse large B-cell lymphoma, chemotherapy, BNP, myocardial infarction, congestive left ventricular heart failure.

Read in PDF(RUS) pdficon

REFERENCES

  1. Морозова А.К., Звонков Е.Е., Кременецкая А.М. и др. Первый опыт применения модифицированной программы NHL-BFM-90 при лечении пер- вичной диффузной B-крупноклеточной лимфосаркомы костей и мягких тканей с факторами неблагоприятного прогноза. Тер. арх. 2009; 7: 61–5. [Morozova A.K., Zvonkov Ye.Ye., Kremenetskaya A.M., et al. Initial experience with using modified NHL-BFM-90 program in management of primary diffuse large B-cell lymphosarcoma of bones and soft tissues with unfavorable prognostic factors. Ter. arkh. 2009; 7: 61–5. (In Russ.)].
  2. Myers C. The Role of Iron in Doxorubicin-Induced Cardiomyopathy. Sem. Oncol. 1998; 25(4 Suppl. 10): 10–4.
  3. Орел Н.Ф. Кардиотоксичность антрациклинов: возможности преодо- ления. Совр. онкол. 2004; 3: 121–4. [Orel N.F. Cardiotoxicity of anthracyclines: potential overcoming. Sovr. onkol. 2004; 3: 121–4. (In Russ.)].
  4. Bhardwaj A., Rehman S.U., Mohammed A. et al. Design and methods of the Pro-B Type Natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) Study. Am. Heart J. 2010; 159: 532–8.el.
  5. Maisel A.S., Krishnaswamy P., Nowak R.M. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002; 347: 161–7.
  6. Sadanandan S., Cannon C.P., Chekuri K. et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2004; 44: 564–8.
  7. Елисеев О.М. Натрийуретические пептиды: эволюция знаний. Тер. арх. 2003; 9: 40–5. [Yeliseyev O.M. Natriuretic peptides: knowledge evolution. Ter. arkh. 2003; 9: 40–5. (In Russ.)].
  8. Gackowskia A., Isnarda R., Golmardc J.-L. et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur. Heart J. 2004; 25: 1788–96.
  9. Days J., Lehman R., Glasziou P. The Role of BNP Testing in Heart Failure. Am. Fam. Phys. 2006; 74(11): 1893–900.
  10. Harrison A., Morrison L.K., Krishnaswamy P. et al. B-Type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann. Emerg. Med. 2002; 39: 131–8.
  11. Leya F.S., Arab D., Joyal D. et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J. Am. Coll. Cardiol. 2005; 45: 1900–2.

Radiotherapy in combined treatment of patients with diffuse large B-cell lymphoma

CLINICAL PRESENTATION, DIAGNOSIS, AND MANAGEMENT OF LYMPHOID MALIGNANCIES , , ,

Yu.N. Vinogradova, N.V. Ilin, D.V. Larionov, M.M. Khodzhibekova, N.A. Kostenikov, and L.I. Korytova

Russian Research Centre for Radiology and Surgical Technologies, RF Ministry of Health, Saint Petersburg, Russian Federation

ABSTRACT

The study included 86 primary patients (age: 18–83) with diffuse large B-cell lymphoma, I to IV stages, who received (R)-CHOP regimen and radiotherapy at the CRIRR (at present RRCRST) over the period 2000–2012. The follow-up period median was 42 months (5–120 months). Positron emission tomography (PET) with 18F-FDG was performed in 45 patients at the various follow-up time-points. In all patients, the changes of hematologic indices were observed using baseline, pre-, and postradiation measurements. After combined treatment completed, remission was achieved in 80 out of 86 (93.0 %) patients, including complete or uncertain complete remission and partial remission in 86.0 % and 7.0 %, respectively. During the initial therapy, disease progression occurred in 6 (7.0 %) patients. After the chemotherapy stage, complete remission was noted in 56 (65.1 %) patients only. Additional radiotherapy promoted the increase in the rate of complete and uncertain complete response by 21.9 %. Disseminated disease relapses developed in 2 out of 80 (2.5 %) patients. The complete response rate in the patients who received radiotherapy using the various fractionation regimens was similar. 5-year overall, relapse-free, and progression–free survival were 89.7 ± 3.9 %, 96.6 ± 2.4 %, and 85.4 ± 4.8 %, respectively. In 20.6 % of the patients examined after chemotherapy, PET gave positive results, while after the radiotherapy stage, all the patients examined at this time-point were PET-negative. Radiotherapy was accompanied by mainly I–II grade hematologic toxicity, and in 16–58 % of patients, no interruption of treatment were required. Neutropenia and thrombocytopenia occurred more frequently at the twice-a-day irradiation.

Keywords: diffuse large B-cell lymphoma, radiotherapy, positron emission tomography, hematologic toxicity.

Read in PDF (RUS)pdficon

References

  1. Friedberg J.W. Pros — R-CHOP is the current standard therapy for patients with advanced stage DLBCL. Hematol. Oncol. Special Issue: 12th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, June 19–22, 2013; 31: Abstract 004.
  2. Miller T.P., Dahlberg S., Cassady J.R. et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high grade non Hodgkin’s lymphoma. N. Engl. J. Med. 1998; 339: 21–6.
  3. Ng A.K., Mauch P.M. Role of radiation therapy in localized aggressive lymphoma. J. Clin. Oncol. 2007; 25: 757–9. 4. Gospodarowicz M.K. Radiotherapy in non-Hodgkin lymphomas. Ann. Oncol. 2008; 19(4): 47–50.
  4. Illidge T.X. When should radiotherapy be used in lymphoma? Ann. Oncol. 2011; 22(4): 57–60.
  5. Tilly H., Vitolo U., Walewski J. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012; 23(7): 78–82.
  6. Асланиди И.П., Мухортова О.В., Шурупова И.В. и др. Позитронно- эмиссионная томография: уточнение стадии болезни при злокачественных лимфомах. Клин. онкогематол. 2010; 3(2): 119–29.[Aslanidi I.P., Mukhortova O.V., Shurupova I.V. i dr. Pozitronnoemissionnaya tomografiya: utochneniye stadii bolezni pri zlokachestvennykh limfomakh (Positron emission tomography: ascertaining disease stage in malignant lymphomas. In: Clin. oncohematol.). Klin. onkogematol. 2010; 3(2): 119–29.]
  7. Yahalom J., Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann. Oncol. 2002; 13(1): 79–83.
  8. Cheson B., Horning S., Coiffer B. et al. Report of an International Workshop to standardize Response Criteria for Non-Hodgkin’s Lymphomas. J. Clin. Oncol. 1999; 17(4): 1244–53.
  9. Cheson B., Pfistner B., Juweid M. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25: 579–86.
  10. Cox J., Stetz J., Pajak T. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC). Intern. J. Radiat. Oncol. Biol. Phys. 1995; 31: 1341–6.
  11. Morschhauser F. R-CHOP is not the standard for high-risk DLBCL. Hematological Oncology. Special Issue: 12th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, June 19–22, 2013; 31: Abstrфсе 005.
  12. Zelenetz А.О., Abramson J.S., Advani R.H. et al. NCCN Clinical Practice Guidelines in Oncology non Hodgkin’s lymphomas. J. Natl. Compr. Canc. Netw. 2010; 8: 288–334.
  13. Phan J., Mazloom A., Jeffrey Medeiros L. et al. Benefit of consolidative radiation therapy in patients with diffuse large В cell lymphoma treated with RCHOP chemotherapy. J. Clin. Oncol. 2010; 28: 4170–6.
  14. Bonnet С., Fillet G., Mournier N. et al. CHOP alone compared with CHOP plus radiotherapy for localised aggressive lymphoma in elderly patients a study by the Groupe d Etude des Lymphomes de l’ Adulte. J. Clin. Oncol. 2007; 25: 787–92.
  15. Dabaja B., Vanderplas A., Abel G. et al. Pole of radiation in patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era: a comprehensive analysis from the National Comprehensive Cancer Network (NCCN) lymphoma outcomes project. Hematol. Oncol. 2013; 31(1): 136.
  16. Zwick C., Held G., Ziepert M. et al. The role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Results from two prospective trials of the DSHNHL. Hematol. Oncol. 2013; 31(1): 137.
  17. Sehn L.H., Klasa R., Shenkier T. et al. Long-term experience with PETguided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol. Oncol. 2013; 31(1): 137.
  18. Gang A. O., Strom C., Pedersen M. et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann. Oncol. 2012; 23(1): 147–53.
  19. Bosly A., Bron D., Van Hoof A. et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann. Hematol. 2008; 87: 277–83.
  20. Pfreundschuh M., Schubert J., Ziepert M. et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2): 105–16.
  21. Persky D.O., Unger J.M., Speir C.M. et al. Phase II study of rituximab plus 3 cycles of CHOP and involved field radiotherapy for patients with limited stage aggressive B cell lymphoma: Southwest Oncology Group Study 0014. J. Clin. Oncol. 2008; 26: 2258–63.
  22. Linch D. Today’s treatment of diffuse large B-cell lymphomas in adults. Hematol. Educ. (The education program for the annual congress of the EHA) 2011; 5: 210–6. 24. Jaeger U., TrnenyM., Melzer H. et al. Rituximab maintenance treatment versus observation in patients with aggressive B-cell lymphoma: results of the AGMT NHL13 trial. Hematol. Oncol. 2013; 31(1): 136.
  23. Swinnen L.J., Li H., Quon A. et al. Response-adapted therapy and predictive value of mid-treatment PET scanning for diffuse large B-cell lymphoma. ECOG study E3404. Hematol. Oncol. 2013; 31(1): 101.
  24. Mamot C., Klingbiel D., Renner C. Final results of a prospective evaluation of the predictive value of interim PET in patients with DLBCL under R-CHOP-14 (SAKK 38/07). Hematol. Oncol. 2013; 31(1): 100.
  25. Moskowitz C.H., Schoder H., Hamlin P.A. et al. Evaluation of dual tracer (FLT and FDG) PET imaging as part of risk-adapted therapy for patients (PTS) with advanced stage diffuse large B-cell lymphoma (DLBCL). Hematol. Oncol. 2013; 31(1): 101.